Overview
Portfolio
More
Gpg Ventures
Portfolio
41+
Employees
N/A
Founded
N/A
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedFund details
Funds
GPG HOF
Vintage 2018 • $9.1M
GPG HOF II
Vintage 2021 • $20.5M
Sources
Gpg Ventures
Portfolio
41+
Employees
N/A
Founded
N/A
AUM
N/A
Funds
GPG HOF · Vintage 2018 • $9.1M
GPG HOF II · Vintage 2021 • $20.5M
Showing 24 of 24 matched portfolio companies
Alto operates a dedicated fleet with employee drivers and user-friendly applications to provide reliable and safe transportation services. The company ensures consistent ride quality, addressing the need for dependable and secure travel options in urban environments.
Funding: $131.5M
Rough estimate of the amount of funding raised
Funding: $131.5M
Rough estimate of the amount of funding raised
Ataia Medical develops the SPEAX Communication System, which consists of a patch attached to a non-invasive ventilation mask and a battery-powered communicator, allowing patients to verbally interact with their care team and loved ones. This technology addresses the challenge of communication barriers faced by patients using CPAP and BiPAP devices, enabling them to maintain essential social interactions without interrupting their therapy.
Funding: $330.0K
Rough estimate of the amount of funding raised
Funding: $330.0K
Rough estimate of the amount of funding raised
Develops small molecule therapeutics targeting mutated APC (_APCmut_) colorectal cancer cells through synthetic lethality, with minimal toxicity to normal cells. The lead candidate, BT-1501, demonstrates significant tumor growth inhibition in preclinical models and is set to enter Phase 1 trials in 2025, addressing a critical unmet need in a disease responsible for over 1 million deaths annually.
Funding: $14.0M
Rough estimate of the amount of funding raised
Funding: $14.0M
Rough estimate of the amount of funding raised
Betaliq, Inc. is developing a portfolio of topical glaucoma treatments utilizing the EyeSol® water-free delivery system, which enhances drug absorption and residency time without the need for harmful preservatives. This technology addresses the limitations of traditional eye drops, providing effective treatment while minimizing ocular surface damage.
Founded 2018
Cerene provides an FDA‑cleared, office‑based cryotherapy system that ablates the endometrial lining to treat heavy menstrual bleeding without general anesthesia. Using a single‑use probe, the procedure delivers controlled freezing in under 10 minutes, allowing gynecologists to perform the treatment in a standard exam room with minimal downtime and pain.
40+
1K+Approximate amount of employees
Funding: $5.0M
Rough estimate of the amount of funding raised
Funding: $5.0M
Rough estimate of the amount of funding raised
Corvion develops a fully implanted mechanical circulatory support device, the CORVION LVAD, designed for severe heart failure patients. This system features a high-efficiency pump powered by a small, implantable battery allowing for up to 12 hours of untethered operation. The technology eliminates the need for percutaneous drivelines, offering patients greater mobility and a reduced risk of infection.
5+
200+Approximate amount of employees
Funding: $917.5K
Rough estimate of the amount of funding raised
Funding: $917.5K
Rough estimate of the amount of funding raised
CounterFind utilizes image recognition, artificial intelligence, and human intelligence to detect and remove counterfeit products from online marketplaces and social media platforms. The platform provides real-time reporting and customized anti-counterfeiting strategies, protecting brands from revenue loss and intellectual property theft.
Funding: $750.0K
Rough estimate of the amount of funding raised
Funding: $750.0K
Rough estimate of the amount of funding raised
Earthview provides a continuous emissions monitoring system using IoT technology to detect, locate, and quantify greenhouse gas leaks in real time for the oil and gas sector. This system enables companies to monitor air quality effectively, facilitating compliance with environmental regulations and supporting their sustainability goals.
Funding: $2.4M
Rough estimate of the amount of funding raised
Funding: $2.4M
Rough estimate of the amount of funding raised
LimiFlex has developed the Dynamic Sagittal Tether™, a minimally invasive stabilization device designed for patients with grade I degenerative spondylolisthesis and spinal stenosis. This system preserves natural spinal motion while providing necessary stability post-decompression, offering a viable alternative to traditional spinal fusion, which is often invasive and carries significant risks.
Funding: $10.0M
Rough estimate of the amount of funding raised
Funding: $10.0M
Rough estimate of the amount of funding raised
Genomenon develops the Mastermind Genomic Intelligence Platform, which utilizes AI to analyze and interpret extensive genomic datasets, providing actionable insights for clinical diagnostics and precision therapeutics. The platform enhances variant interpretation efficiency, enabling healthcare professionals to make informed decisions based on a comprehensive database of over 26 million curated genomic variants.
Funding: $5.5M
Rough estimate of the amount of funding raised
Funding: $5.5M
Rough estimate of the amount of funding raised
Gregor Diagnostics is developing a suite of semen-based genomic classifier tests to enhance prostate cancer screening and monitoring, providing high sensitivity and specificity while minimizing the need for invasive biopsies. The technology addresses the limitations of current diagnostics, which often lead to overdiagnosis and unnecessary treatments in a significant number of patients.
Funding: $14.3M
Rough estimate of the amount of funding raised
Funding: $14.3M
Rough estimate of the amount of funding raised
Hypergiant develops AI-enabled decision-making software that transforms complex data into actionable intelligence for the space, defense, and critical infrastructure sectors. Their tools enhance situational awareness and streamline operational efficiency, enabling rapid responses to emerging challenges.
100+
10K+Approximate amount of employees
Funding: $5.0M
Rough estimate of the amount of funding raised
Funding: $5.0M
Rough estimate of the amount of funding raised
Lantern Pharma develops precision oncology therapies using artificial intelligence, machine learning, and genomics to enhance the efficiency and accuracy of drug discovery and development. The company addresses the high costs and lengthy timelines associated with oncology drug development by utilizing a data-driven platform that analyzes over 100 billion data points to identify effective treatment candidates.
Funding: $60.0M
Rough estimate of the amount of funding raised
Funding: $60.0M
Rough estimate of the amount of funding raised
Mission Bio offers the Tapestri Platform, an end‑to‑end single‑cell multi‑omics solution that simultaneously captures targeted DNA variants, surface‑protein markers, and optional RNA reads from thousands of individual cells. This enables researchers to resolve clonal heterogeneity, edit zygosity, and genotype‑phenotype relationships in cancer and gene‑editing studies with subclone detection down to 0.1%.
NovaScan offers MarginScan™, a compact device that uses high‑frequency spectral bioimpedance and AI/ML to provide real‑time, non‑destructive cancer margin assessment during surgery. The system delivers specific electrical signatures of malignant tissue within seconds, enabling surgeons to preserve healthy tissue, reduce re‑operations, and streamline workflow without requiring dedicated pathology resources.
Funding: $3.0M
Rough estimate of the amount of funding raised
Funding: $3.0M
Rough estimate of the amount of funding raised
OncoNano Medicine develops pH-activated polymeric micelles using its ON-BOARD™ platform to deliver anti-tumor agents directly to the tumor microenvironment. This technology targets the variability of pH in cancerous tissues, enhancing the precision and efficacy of cancer therapies.
Founded 2014
Prolocor is developing a precise diagnostic test utilizing advanced biomarker analysis to assess and manage cardiovascular disease risk. This technology addresses the lack of effective diagnostic tools that can guide individualized therapy for patients suffering from atherosclerotic cardiovascular disease.
Funding: $4.9M
Rough estimate of the amount of funding raised
Funding: $4.9M
Rough estimate of the amount of funding raised
Proscia offers the Concentriq enterprise pathology platform, which digitizes anatomic pathology data and integrates AI applications to enhance diagnostic accuracy and efficiency. This technology enables pathology laboratories to achieve full digitization, resulting in faster turnaround times and improved patient care outcomes.
Funding: $9.0M
Rough estimate of the amount of funding raised
Funding: $9.0M
Rough estimate of the amount of funding raised
Radformation develops automation software that enhances radiation treatment planning by streamlining contouring, plan evaluation, and quality assurance processes. This technology enables cancer clinics to improve treatment efficiency and safety while reducing the time spent on administrative tasks.
Funding: $4.8M
Rough estimate of the amount of funding raised
Funding: $4.8M
Rough estimate of the amount of funding raised
Retension Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular health. The company concentrates its research and development efforts on optimizing blood pressure management. Their work aims to advance therapeutic options within the cardiovascular disease space.
Ro operates a telehealth platform that provides online clinics for weight loss, sexual health, hair restoration, and fertility management using clinically proven treatments and prescription medications. The service eliminates the need for insurance and offers free, discreet shipping, making healthcare accessible and convenient for over 2 million members.
Stingray Therapeutics develops next-generation immunotherapies that harness the full potential of the immune system to target and eliminate cancer cells. Their approach addresses the limitations of traditional cancer treatments by enhancing immune response, aiming to improve patient outcomes across various cancer types.
Funding: $8.6M
Rough estimate of the amount of funding raised
Funding: $8.6M
Rough estimate of the amount of funding raised
Work Shield provides a secure reporting platform that allows employees to report workplace misconduct anonymously, while its team conducts thorough investigations and offers objective resolution recommendations. This solution addresses the fear of retaliation and bias in internal investigations, ensuring a safer and more equitable workplace environment for over 150,000 employees across 300 clients.
Funding: $10.1M
Rough estimate of the amount of funding raised
Funding: $10.1M
Rough estimate of the amount of funding raised
Worlds provides an AI platform that utilizes real-time video and sensor data to create custom AI applications for enterprise operations. This technology enables companies to automate processes such as hazard detection, asset tracking, and environmental compliance, significantly reducing human effort and improving operational efficiency.
Funding: $40.5M
Rough estimate of the amount of funding raised
Funding: $40.5M
Rough estimate of the amount of funding raised
Showing 12 of 17 unmatched portfolio companies